AMPH vs SPRY
AMPH: Amphastar manufactures technically complex generic and proprietary injectable, inhalation, and intranasal drugs with high barriers to entry, leveraging proprietary formulation and manufacturing capabilities to compete in high-margin, supply-constrained markets. SPRY: Biopharmaceutical company commercializing neffy, the only FDA-approved needle-free intranasal epinephrine for emergency anaphylaxis treatment.
Side-by-side fundamentals
| Metric | AMPH | SPRY | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $19.30 | $6.06 | |
| Market cap as of 2026-07-23 | $864M | $602M | |
| P/E as of 2026-07-23 | 10.90 | n/a | |
| PEG as of 2026-07-23 | -1.77 | -0.00 | AMPH lower |
| Net margin as of 2026-07-23 | +11.0% | -200.0% | AMPH higher |
| Gross margin as of 2026-07-23 | +47.3% | +74.1% | SPRY higher |
| Operating margin as of 2026-07-23 | +16.2% | -204.5% | AMPH higher |
| ROE as of 2026-07-23 | +10.2% | -153.6% | AMPH higher |
| ROA as of 2026-07-23 | +4.8% | -60.9% | AMPH higher |
| Debt / equity as of 2026-07-23 | 0.79 | 1.57 | AMPH lower |
| Revenue growth (YoY) as of 2026-07-23 | -1.4% | +1.9% | SPRY higher |
| Revenue CAGR (3y) SEC XBRL | +13.0% | +300.1% | SPRY higher |
| Beta as of 2026-07-23 | 0.91 | 1.02 | |
| 1-year return as of 2026-07-22 close | -7.6% | -64.4% | AMPH higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.